TerminatedNCT01131559
Adjunctive Lisdexamfetamine (LDX) in Depression in bipolarity
Medication studyAges 18–55United States
Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- MasonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJanuary 2010
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 50
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01131559
- Official title
Show the full official title
Adjunctive Lisdexamfetamine in Bipolar Depression
Recruitment & locations
TerminatedMason
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Does this study involve medication?
Yes. The study involves medication, including Lisdexamfetamine and Placebo control.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.